FDA-Approved Medications for Opioid Addiction: 2025 Treatment Options

Medication-Assisted Treatment Saves Lives

Medication-assisted treatment (MAT) for opioid use disorder reduces overdose deaths, improves treatment retention, and helps people rebuild their lives. The FDA has approved four medications for this purpose: buprenorphine, methadone, naltrexone, and lofexidine. In 2025, new delivery methods and regulatory changes are making these treatments more accessible than at any point in the overdose crisis.

Despite strong evidence, only about 22% of people with opioid use disorder receive MAT. Understanding your treatment options is the first step toward closing that gap.

Current FDA-Approved Options

Buprenorphine: Available as sublingual tablets, films, extended-release injections (Sublocade, Brixadi), and implants
Methadone: Administered as oral solution or tablets through Opioid Treatment Programs
Naltrexone: Available as daily oral tablets or monthly extended-release injection (Vivitrol)
Lofexidine: Approved for managing acute opioid withdrawal symptoms

What Changed in 2025

Several developments have improved MAT accessibility this year.

Expanded injection sites for Sublocade. In February 2025, the FDA approved expanded injection sites for buprenorphine extended-release injection. Providers now administer the monthly shot in the thigh, buttock, and back of the upper arm, in addition to the abdomen. This gives patients and providers more flexibility and reduces discomfort from repeated injections at a single site.

Streamlined initiation process. Starting Sublocade now requires only one sublingual buprenorphine dose and a brief observation period before the first injection. This removes a significant barrier for patients who previously needed multiple office visits before starting injectable treatment.

“The expansion of buprenorphine injection sites gives clinicians needed flexibility and reduces a common complaint among patients about injection site rotation.” — FDA Prescribing Update, February 2025

How Each Medication Works

Buprenorphine

Buprenorphine is a partial opioid agonist. It activates opioid receptors in the brain enough to reduce cravings and withdrawal symptoms without producing the full euphoria of drugs like heroin or fentanyl. This ceiling effect also makes overdose less likely when taken as prescribed.

The extended-release injection forms (Sublocade and Brixadi) provide steady medication levels for a month, eliminating the need for daily dosing and reducing the risk of diversion.

Methadone

Methadone is a full opioid agonist that has been used for decades. It reduces cravings and withdrawal while blocking the effects of other opioids. Methadone requires dispensing through certified Opioid Treatment Programs, which means regular clinic visits. It remains the gold standard for patients who do not respond to buprenorphine.

Naltrexone

Naltrexone works differently. It blocks opioid receptors entirely, preventing any opioid from producing effects. The monthly injection (Vivitrol) is the preferred form because it eliminates adherence concerns. Naltrexone requires full detoxification before starting, which limits its use in some settings.

Treatments on the Horizon

Naltrexone implants: A six-month implant is in Phase 2 clinical trials at Columbia University, with potential FDA approval as early as 2026
GLP-1 agonists: Early research shows these weight-loss medications reduce opioid overdose rates. CNS-targeted formulations for addiction could reach approval by 2026
Long-acting methadone: Researchers are developing a reformulated version that provides monthly dosing, eliminating daily clinic visits

Choosing the Right Medication

The best medication depends on your specific situation, including your substance use history, medical conditions, lifestyle, and personal preferences. A qualified addiction medicine provider will help you evaluate options and develop a treatment plan. Every FDA-approved medication for opioid use disorder reduces overdose death risk. Starting any one of them is better than starting none.